Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer
NCT ID: NCT05513664
Last Updated: 2022-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
80 participants
OBSERVATIONAL
2022-09-30
2023-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer
NCT05132777
Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC
NCT05215951
JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations
NCT06391944
Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC
NCT03133234
Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer
NCT04448379
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Osimertinib
80 or 160 mg/qd
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The result of EGFR 20ins is positive detected by tissue, blood, pleural fluid or cerebrospinal fluid;
3. Have received osimertinib treatment after detection of EGFR 20ins;
4. Age of 18 years or above;
5. Information about tumor outcome evaluation is required at least once after osimertinib treatment (such as tumor imaging data, description of efficacy evaluation in medical records, etc.).
Exclusion Criteria
2. Patients harboring EGFR exon20 insertion mutation and also have other EGFR TKI-sensitizing EGFR mutations, such as G719X mutation in exon 18, exon 19 deletion mutation (19 del), exon 20 T790M or S768I mutation, exon 21 L858R mutation, or L861Q mutation.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
INDUSTRY
Shanghai JMT-Bio Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Affiliated Hospital of Hebei University
Baoding, , China
Beijing Cancer Hospital
Beijing, , China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, , China
Chinese People's Liberation Army General Hospital
Beijing, , China
Chongqing Cancer Hospital
Chongqing, , China
Southwest Hospital of Army Medical University
Chongqing, , China
Fujian Cancer Hospital
Fuzhou, , China
Sun Yat-sen University Cancer Center
Guangzhou, , China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, , China
The First Affiliated Hospital of Sun Yat-Sen University
Guangzhou, , China
Anhui Cancer Hospital
Hefei, , China
Shandong Cancer Hospital
Jinan, , China
Nanjing Chest Hospital
Nanjing, , China
Fudan University Cancer Hospital
Shanghai, , China
Shanghai Chest Hospital
Shanghai, , China
Shanxi Provincial People's Hospital
Shanxi, , China
The Fourth Hospital of Hebei Medical University
Shijia Zhuang, , China
West China Hospital of Sichuan University
Sichuan, , China
Shanxi Cancer Hospital
Taiyuan, , China
Huazhong University of Science Tongji Hospital, Tongji Medical College
Wuhan, , China
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Wuhan, , China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, , China
First Affiliated Hospital of Zhengzhou University
Zhengzhou, , China
Henan Cancer Hospital
Zhengzhou, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Aimin Zang
Role: primary
Jian Fang
Role: primary
Yan Wang
Role: primary
Yi Hu
Role: primary
Xia Chen
Role: primary
Xiangdong Zhou
Role: primary
Wu Zhuang
Role: primary
Chengzhi Zhou
Role: primary
Yubiao Guo
Role: primary
Hu Liu
Role: primary
Xiaoyong Tang
Role: primary
Yong Lin
Role: primary
Zhihuang Hu
Role: primary
Wei Zhang
Role: primary
Shuili Wang
Role: primary
Da Jiang
Role: primary
Feng Luo
Role: primary
Wei Guo
Role: primary
Qian Chu
Role: primary
Xiaorong Dong
Role: primary
Yu Yao
Role: primary
Xingya Li
Role: primary
Huijuan Wang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JMT101-010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.